Review:
Sglt2 Inhibitors
overall review score: 4.2
⭐⭐⭐⭐⭐
score is between 0 and 5
SGLT2 inhibitors (sodium-glucose co-transporter 2 inhibitors) are a class of oral medications primarily used to treat type 2 diabetes mellitus. They work by blocking the SGLT2 protein in the kidneys, which reduces glucose reabsorption and promotes its excretion through urine, thereby helping to lower blood sugar levels. In addition to glycemic control, they have been associated with benefits such as weight loss and cardiovascular protection.
Key Features
- Reduce blood glucose levels by promoting urinary glucose excretion
- Oral administration with once-daily dosing options
- Associated with weight loss and potential cardiovascular benefits
- Variety of agents within the class, such as canagliflozin, dapagliflozin, and empagliflozin
- May have additional benefits like lowering blood pressure
Pros
- Effective at lowering blood sugar levels in type 2 diabetes
- Promotes weight loss, beneficial for overweight patients
- Provides cardiovascular and renal protective effects
- Convenient oral dosing regimen
Cons
- Risk of urinary tract infections and genital infections
- Potential side effects include dehydration, hypotension, and ketoacidosis
- Not suitable for patients with certain renal impairments
- Long-term safety data is still evolving